PDF
ePub
Citation
Print
Abstract
Chronic graft-versus-host disease (GVHD) is the most frequent late complication after hematopoietic cell transplantation and has a major impact on the quality of life and survival. As the pathophysiology of GVHD is still incompletely understood, it has been difficult to design effective prophylactic regimens. However, prevention of acute GVHD appears to result in a lower incidence of chronic GVHD. The use of younger, non-allo-sensitized donors, preferentially of the same sex as the patient, and the use of stem cells other than G-CSF-mobilized peripheral blood stem cells, are associated with a decreased frequency of chronic GVHD. Further, the incorporation of thymoglobulin into the conditioning regimen has been demonstrated as beneficial to reduce chronic GVHD and delayed complications.
REFERENCES
1). Duell T., van Lint MT., Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT working party on late effects and EULEP Study group on late effects. European group of blood and marrow transplantation. Ann Intern Med. 1997. 126:184–92.
2). Deeg HJ., Leisenring W., Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998. 91:3637–45.
3). Glucksberg H., Storb R., Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974. 18:295–304.
4). Mielcarek M., Martin PJ., Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003. 102:756–62.
5). Mielcarek M., Burroughs L., Leisenring W, et al. Prognostic relevance of “early-onset” graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. Br J Haematol. 2005. 129:381–91.
6). Filipovich AH., Weisdorf D., Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005. 11:945–56.
7). Hess AD., Jones RJ. Autologous graft-versus-host disease. Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. 2nd ed.Boston: Blackwell Science;1999. p. 342–8.
8). Storb R., Prentice RL., Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983. 308:302–7.
9). Cutler C., Giri S., Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001. 19:3685–91.
10). Zaucha JM., Gooley T., Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001. 98:3221–7.
11). Wagner JE., Barker JN., Defor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002. 100:1611–8.
12). Sullivan KM., Agura E., Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991. 28:250–9.
13). Remberger M., Aschan J., Lönnqvist B, et al. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. Eur J Haematol. 2001. 66:50–6.
14). Oh H., Loberiza FR Jr., Zhang MJ, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005. 105:1408–16.
15). Randolph SSB., Gooley TA., Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic cell transplants. Blood. 2004. 103:347–52.
16). Miklos DB., Kim HT., Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005. 105:2973–8.
17). Holmes JA., Whittaker JA. Histocompatibility antigen DR4 is associated with chronic graft-versus-host disease in the south Wales population. Br J Haematol. 1989. 73:424.
18). Pawelec G., Müller CA., Haen M., Ehninger G. Chronic graft-versus-host disease and HLA-DR4 in the southern German population. Br J Haematol. 1990. 75:295–6.
19). Kim HJ., Park SJ., Im HW, et al. The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea. Int J Hematol. 2002. 76:267–71.
20). Ho VT., Mirza NQ., Junco Dd D., Okamura T., Prze-piorka D. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant. 2003. 32:771–5.
21). Jenkins MK., Schwartz RH., Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science. 1988. 241:1655–8.
22). Sakoda Y., Hashimoto D., Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007. 109:1756–64.
23). Zhang C., Todorov I., Zhang Z, et al. Donor CD4＋ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006. 107:2993–3001.
24). Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol. 2004. 79:209–15.
25). Alpdogan O., Schmaltz C., Muriglan SJ, et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 2001. 98:2256–65.
26). Alpdogan O., Muriglan SJ., Eng JM, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2003. 112:1095–107.
27). Sinha ML., Fry TJ., Fowler DH., Miller G., Mackall CL. Interleukin 7 worsens graft-versus-host disease. Blood. 2002. 100:2642–9.
28). Chung B., Dudl E., Toyama A, et al. IL-7 is necessary for induction of experimental graft-versus-host disease (GVHD). Blood. 2003. 102:149a, #514.
29). Weinberg K., Blazar BR., Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001. 97:1458–66.
30). Seggewiss R., Einsele H. Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation. Semin Hematol. 2007. 44:203–11.
31). Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005. 105:4200–6.
32). Ruggeri L., Capanni M., Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002. 295:2097–100.
33). Chan GW., Foss FM., Klein AK., Sprague K., Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant. 2003. 9:753–9.
34). Chao NJ., Parker PM., Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant. 1996. 2:86–92.
35). Sokos DR., Berger M., Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002. 8:117–30.
36). Kansu E., Gooley T., Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood. 2001. 98:3868–70.
37). Soiffer RJ., Martin P. T-cell depletion of allogeneic hematopoietic stem cell grafts. Atkinson K, Champlin R, Ritz J, editors. Clinical bone marrow and blood stem cell transplantation. 3rd ed.Cambridge, UK: Cambridge University Press;2004. p. 416–25.
38). Wagner JE., Thompson JS., Carter SL., Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005. 366:733–41.
39). Kottaridis PD., Milligan DW., Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000. 96:2419–25.
40). Soiffer RJ., Weller E., Alyea EP, et al. CD6＋ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001. 19:1152–9.
41). Bacigalupo A., Lamparelli T., Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001. 98:2942–7.
42). Bacigalupo A., Lamparelli T., Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006. 12:560–5.
43). Remberger M., Svahn BM., Mattsson J., Ringdén O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004. 78:122–7.
44). Remberger M., Svahn BM., Hentschke P, et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999. 24:823–30.
45). Deeg HJ., Storer BE., Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006. 12:573–84.
46). Schetelig J., Bornhäuser M., Kiehl M, et al. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation—a retrospective analysis. Bone Marrow Transplant. 2004. 33:483–90.
47). Kim HJ., Min WS., Eom KS, et al. Anti-leukemic role of acute GVHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukemia. Bone Marrow Transplant. 2007. 40:1069–74.
48). Lopez M., Clarkson MR., Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4＋CD25＋Foxp3＋ regulatory T cells. J Am Soc Nephrol. 2006. 17:2844–53.
49). Maury S., Mary JY., Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001. 115:630–41.
50). Cutler C., Miklos D., Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006. 108:756–62.
51). Stewart BL., Storer B., Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004. 104:3501–6.
52). Akpek G., Lee SJ., Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multi-center study. Blood. 2003. 102:802–9.
53). Lee SJ., Vogelsang G., Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003. 9:215–33.
54). Couriel D., Carpenter PA., Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant. 2006. 12:375–96.
XML Download